183 related articles for article (PubMed ID: 38164172)
21. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of CD73 associates with T cell exhaustion in AML patients.
Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
[TBL] [Abstract][Full Text] [Related]
23. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.
Kordaß T; Osen W; Eichmüller SB
Front Immunol; 2018; 9():813. PubMed ID: 29720980
[TBL] [Abstract][Full Text] [Related]
24. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
25. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
26. CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway.
Xue F; Wang T; Shi H; Feng H; Feng G; Wang R; Yao Y; Yuan H
Cancer Sci; 2022 Aug; 113(8):2704-2715. PubMed ID: 35657703
[TBL] [Abstract][Full Text] [Related]
27. Expression of ADK-S and ADK-L Isoforms and Their Association with CD39/CD73/A2aR in Colorectal Cancer.
Zhulai GA; Shibaev MI
Bull Exp Biol Med; 2023 Nov; 176(1):91-95. PubMed ID: 38085399
[TBL] [Abstract][Full Text] [Related]
28. Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5'NT/CD73 in metastasis as potential prognostic factor.
Cappellari AR; Rockenbach L; Dietrich F; Clarimundo V; Glaser T; Braganhol E; Abujamra AL; Roesler R; Ulrich H; Battastini AM
PLoS One; 2012; 7(10):e47468. PubMed ID: 23094051
[TBL] [Abstract][Full Text] [Related]
29. circHMGCS1-016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma.
Xu YP; Dong ZN; Wang SW; Zheng YM; Zhang C; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Peng R; Tang MC; Bai DS; Huang XY; Guo CY
J Exp Clin Cancer Res; 2021 Sep; 40(1):290. PubMed ID: 34526098
[TBL] [Abstract][Full Text] [Related]
30. Cell type- and tissue-specific functions of ecto-5'-nucleotidase (CD73).
Minor M; Alcedo KP; Battaglia RA; Snider NT
Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1079-C1092. PubMed ID: 31461341
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O; Belisario DC; Compagno M; Giovinazzo F; Bracci C; Pastorino U; Horenstein A; Malavasi F; Ferracini R; Scala S; Sozzi G; Roz L; Roato I; Bertolini G
Front Immunol; 2020; 11():02168. PubMed ID: 33123122
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
33. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro.
Wu R; Chen Y; Li F; Li W; Zhou H; Yang Y; Pei Z
Oncol Rep; 2016 Mar; 35(3):1750-6. PubMed ID: 26708311
[TBL] [Abstract][Full Text] [Related]
34. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
Stagg J; Divisekera U; McLaughlin N; Sharkey J; Pommey S; Denoyer D; Dwyer KM; Smyth MJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1547-52. PubMed ID: 20080644
[TBL] [Abstract][Full Text] [Related]
36. 5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells.
Shi E; Wu Z; Karaoglan BS; Schwenk-Zieger S; Kranz G; Abdul Razak N; Reichel CA; Canis M; Baumeister P; Zeidler R; Gires O
J Biomed Sci; 2023 Aug; 30(1):72. PubMed ID: 37620936
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Ecto-5'-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix.
Zhou P; Zhi X; Zhou T; Chen S; Li X; Wang L; Yin L; Shao Z; Ou Z
Cancer Biol Ther; 2007 Mar; 6(3):426-31. PubMed ID: 17471030
[TBL] [Abstract][Full Text] [Related]
38. CD8
Panigrahi S; Bazdar DA; Albakri M; Ferrari B; Antonelli CJ; Freeman ML; Dubyak G; Zender C; Sieg SF
Eur J Immunol; 2020 Dec; 50(12):2055-2066. PubMed ID: 32548862
[TBL] [Abstract][Full Text] [Related]
39. Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease.
Tsukamoto H; Chernogorova P; Ayata K; Gerlach UV; Rughani A; Ritchey JW; Ganesan J; Follo M; Zeiser R; Thompson LF; Idzko M
Blood; 2012 May; 119(19):4554-64. PubMed ID: 22262774
[TBL] [Abstract][Full Text] [Related]
40. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
